within Pharmacolibrary.Drugs.ATC.B;

model B06AX03
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.74,
    Cl             = 6.866666666666668e-05,
    adminDuration  = 600,
    adminMass      = 1500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.333,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0035,
    Tlag           = 19.8,            
    Vdp             = 2.16,
    k12             = 8.02,
    k21             = 8.02
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B06AX03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Voxelotor is an oral, small-molecule inhibitor of hemoglobin S polymerization, used in the treatment of sickle cell disease (SCD). It increases the affinity of hemoglobin for oxygen, thereby inhibiting sickling of red blood cells. Voxelotor is approved for use in the treatment of sickle cell disease in patients aged 4 years and older.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters were characterized in healthy volunteers and patients with sickle cell disease, following once-daily oral administration.</p><h4>References</h4><ol><li><p>Preston, RA, et al., &amp; Washington, C (2021). Pharmacokinetics of Voxelotor in Patients With Renal and Hepatic Impairment. <i>Journal of clinical pharmacology</i> 61(4) 493–505. DOI:<a href=&quot;https://doi.org/10.1002/jcph.1757&quot;>10.1002/jcph.1757</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33084052/&quot;>https://pubmed.ncbi.nlm.nih.gov/33084052</a></p></li><li><p>Hutchaleelaha, A, et al., &amp; Lehrer-Graiwer, J (2019). Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease. <i>British journal of clinical pharmacology</i> 85(6) 1290–1302. DOI:<a href=&quot;https://doi.org/10.1111/bcp.13896&quot;>10.1111/bcp.13896</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30743314/&quot;>https://pubmed.ncbi.nlm.nih.gov/30743314</a></p></li><li><p>Howard, J, et al., &amp; Lehrer-Graiwer, J (2019). A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease. <i>Blood</i> 133(17) 1865–1875. DOI:<a href=&quot;https://doi.org/10.1182/blood-2018-08-868893&quot;>10.1182/blood-2018-08-868893</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30655275/&quot;>https://pubmed.ncbi.nlm.nih.gov/30655275</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B06AX03;
